Key Stats for AbbVie Stock
- Current Price: $262.82
- Target Price (Mid): ~$362
- Street Target: ~$279
- Potential Total Return: ~38%
- Annualized IRR: ~8% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
AbbVie (ABBV) has two pricing events landing on the same day. On January 1, 2027, Medicare’s negotiated price for Vraylar, AbbVie’s antipsychotic, takes effect at $770 for a 30-day supply, 44% below its 2024 list price of $1,376. On October 2, AbbVie said the Health Resources and Services Administration (HRSA) approved it for a 340B Rebate Model Pilot that starts the same day for Vraylar, Linzess, and Imbruvica.
340B requires drugmakers to discount drugs for safety-net hospitals and clinics. AbbVie’s investor relations materials show second-quarter immunology revenue, led by Skyrizi and Rinvoq, up 15.1%.
Three Negotiated Drugs, $7.4 Billion in 2025 Sales
All three pilot drugs carry Medicare negotiated prices. Imbruvica’s $9,319 monthly price took effect January 1, 2026, and in 2027 Linzess falls to $136 from its 2024 list price of $539. AbbVie says a rebate model improves transparency and prevents duplicate discounts.
TIKR data shows the three drugs brought in $7,397 million in 2025, 12.1% of AbbVie’s $61,160 million total. In the first half of 2026, Vraylar grew 18.6% and Linzess 42.1%, while Imbruvica, already under its negotiated price, fell 27.1%, a decline AbbVie’s release does not explain. Only 340B-eligible dispenses run through the pilot, and list-price comparisons overstate the hit because rebates already push net prices below list.
See historical and forward estimates for AbbVie stock (It’s free!) >>>
A Pilot Already Fought Over in Court
Chairman and CEO Robert Michael said at the September 15 Morgan Stanley conference that drugmakers support the program’s original intent, “but it’s clear that the overly broad definition of a patient has led to a level of abuse over the years.” He added, “And frankly, it’s taking R&D investment away from the industry.” In 2025, the American Hospital Association called the original pilot a response to a “nonexistent” integrity problem.
The first version of the pilot was vacated in court before HRSA relaunched it on August 3, 2026. Vraylar’s runway is also limited, with its listed U.S. patents expiring between 2029 and 2030.
AbbVie Is Taking the Pricing Fight to Germany
Michael also cited “a lot of focus on, I’d say, foreign freeloading,” saying AbbVie has “highlighted to the USTR various examples of unfair practices.” On September 22, AbbVie General Counsel Perry Siatis testified at USTR’s public hearing in its Section 301 investigation into Germany’s drug pricing, which USTR opened on June 18.
Germany is a small market for AbbVie: TIKR data shows it produced $1,738 million of 2025 revenue, 2.8% of the total, against $46,603 million, or 76.2%, from the U.S. AbbVie argues that Germany’s pricing decisions influence policymakers globally, so the likelier payoff is a narrower gap between U.S. and overseas prices, which Michael wants brought “closer together,” rather than more German sales.
The core business gives AbbVie room to wait. Consensus sees 2027 revenue of around $73.5 billion, up roughly 9% from 2026 estimates. On July 31, AbbVie beat TIKR’s second-quarter EPS consensus but trimmed 2026 adjusted EPS guidance by $0.04 at the midpoint, to $13.87 to $14.07, as dilution from its Apogee Therapeutics acquisition outweighed overperformance, and shares fell 2.33%.
See how AbbVie performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $262.82
- Target Price (Mid): ~$362
- Potential Total Return: ~38%
- Annualized IRR: ~8% / year
See analysts’ growth forecasts and price targets for AbbVie stock (It’s free!) >>>
The TIKR model’s mid-case values AbbVie at around $362 by December 31, 2030, a total return of around 38%, or about 8% a year. Its mid-case assumptions, set across a 2025 to 2035 forecast, call for revenue growth near 5%, net income margins near 42%, and a slightly lower P/E. Michael said, “I think there’s obviously more room for multiple expansion as the pipeline matures,” but the target does not depend on it.
- Revenue drivers: Skyrizi and Rinvoq share gains, plus newer launches offsetting the 2027 price resets.
- Margin driver: Operating leverage as one-time acquired R&D charges fade.
- Primary risk: Wider pricing pressure from more negotiated drugs, a court reversal of the pilot, or Vraylar generics.
- Upside: The high case assumes around 5% growth, around 44% margins, and a slightly rising P/E.
- Downside: The low case assumes around 4% growth, around 40% margins, and P/E compression near 2% a year.
Conclusion
AbbVie reports third-quarter results before the market opens on October 30. Vraylar grew 18.9% to $1,071 million in the second quarter, and holding double-digit growth into the January reset would show the cut landing on an expanding base. A 2027 outlook well below the roughly 9% consensus would mean the pricing squeeze is arriving faster than the stock assumes.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
So what is AbbVie stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what AbbVie could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
